Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
SUMMARY
According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2022'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2022' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5 and 12 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Gastric Cancer, Metastatic Renal Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Hematological Tumor, Melanoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Epithelial Ovarian Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified Neurologic Disorders, Ureter Cancer and Urethral Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2022'; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) pipeline Target constitutes close to 22 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes.
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Proto-oncogene tyrosine-protein kinase MER is an enzyme encoded by the MERTK gene. It regulates many physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells. It plays a role in various processes such as macrophage clearance of apoptotic cells, platelet aggregation, cytoskeleton reorganization and engulfment. Functions in the retinal pigment epithelium (RPE) as a regulator of rod outer segments fragments phagocytosis. It also plays an important role in inhibition of Toll-like receptors (TLRs)-mediated innate immune response by activating STAT1.
The report 'Tyrosine Protein Kinase Mer - Drugs In Development, 2022' outlays comprehensive information on the Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 5 and 12 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System and Ophthalmology which include indications Non-Small Cell Lung Cancer, Solid Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Gastric Cancer, Metastatic Renal Cell Carcinoma, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Colorectal Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Hematological Tumor, Melanoma, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Ovarian Cancer, Renal Cell Carcinoma, Soft Tissue Sarcoma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colon Cancer, Epithelial Ovarian Cancer, Gastroesophageal (GE) Junction Carcinomas, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Liposarcoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Oral Cavity (Mouth) Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Retinitis Pigmentosa (Retinitis), Rhabdomyosarcoma, Squamous Non-Small Cell Lung Cancer, Synovial Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified Neurologic Disorders, Ureter Cancer and Urethral Cancer.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- The report reviews Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Dec 15, 2021: Exelixis announces initiation of phase 1b trial evaluating Xl092 in combination with immuno-oncology therapies in patients with advanced solid tumors
Sep 20, 2021: Mirati Therapeutics announces long-term survival results from an exploratory analysis of sitravatinib plus nivolumab in patients with non-squamous non-small cell lung cancer who are resistant to checkpoint inhibitors
Apr 11, 2021: BeiGene presents clinical data on Sitravatinib in combination with Tislelizumab at the AACR Annual Meeting 2021
Mar 18, 2021: Exelixis announces clinical trial collaboration and supply agreement with Merck and Pfizer to evaluate XL092 and Avelumab in various forms of locally advanced or metastatic urothelial carcinoma
Mar 10, 2021: BeiGene announces presentation of clinical data on Sitravatinib in combination with tislelizumab at the AACR Annual Meeting 2021
Jan 26, 2021: Qurient enrolls first patient in Q702 U.S. phase 1 study
Oct 26, 2020: Exelixis announces first patient enrolled in Phase 1 trial cohort evaluating XL092 in combination with Atezolizumab in patients with advanced solid tumors
Oct 09, 2020: Exelixis to present the preclinical profile and initial clinical pharmacokinetics of XL092, its next-generation oral tyrosine kinase inhibitor
Sep 18, 2020: Mirati Therapeutics presents phase 2 data on sitravatinib in combination with nivolumab in urothelial cancer At ESMO Virtual Congress
Jun 22, 2020: RGENIX presents results from preclinical safety and efficacy studies of RGX-019 at the 2020 AACR Annual Meeting
May 26, 2020: Qurient announces U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy
Feb 15, 2020: Mirati Therapeutics announces initial data in Renal Cell Carcinoma from ongoing investigator sponsored clinical trial Of Sitravatinib in combination With Nivolumab at The 2020 ASCO Genitourinary Cancers Syposium
Dec 13, 2019: Sitravatinib plus Tislelizumab show promise in platinum-resistant advanced ovarian cancer
Nov 09, 2019: Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
Oct 23, 2019: Mirati Therapeutics announces presentation of interim phase 2 Sitravatinib data In Urothelial Carcinoma and Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Overview
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Drug Profiles
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Dormant Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Product Development Milestones
Featured News & Press Releases
Dec 15, 2021: Exelixis announces initiation of phase 1b trial evaluating Xl092 in combination with immuno-oncology therapies in patients with advanced solid tumors
Sep 20, 2021: Mirati Therapeutics announces long-term survival results from an exploratory analysis of sitravatinib plus nivolumab in patients with non-squamous non-small cell lung cancer who are resistant to checkpoint inhibitors
Apr 11, 2021: BeiGene presents clinical data on Sitravatinib in combination with Tislelizumab at the AACR Annual Meeting 2021
Mar 18, 2021: Exelixis announces clinical trial collaboration and supply agreement with Merck and Pfizer to evaluate XL092 and Avelumab in various forms of locally advanced or metastatic urothelial carcinoma
Mar 10, 2021: BeiGene announces presentation of clinical data on Sitravatinib in combination with tislelizumab at the AACR Annual Meeting 2021
Jan 26, 2021: Qurient enrolls first patient in Q702 U.S. phase 1 study
Oct 26, 2020: Exelixis announces first patient enrolled in Phase 1 trial cohort evaluating XL092 in combination with Atezolizumab in patients with advanced solid tumors
Oct 09, 2020: Exelixis to present the preclinical profile and initial clinical pharmacokinetics of XL092, its next-generation oral tyrosine kinase inhibitor
Sep 18, 2020: Mirati Therapeutics presents phase 2 data on sitravatinib in combination with nivolumab in urothelial cancer At ESMO Virtual Congress
Jun 22, 2020: RGENIX presents results from preclinical safety and efficacy studies of RGX-019 at the 2020 AACR Annual Meeting
May 26, 2020: Qurient announces U.S. FDA clearance of IND application for Q702, a novel cancer immunotherapy
Feb 15, 2020: Mirati Therapeutics announces initial data in Renal Cell Carcinoma from ongoing investigator sponsored clinical trial Of Sitravatinib in combination With Nivolumab at The 2020 ASCO Genitourinary Cancers Syposium
Dec 13, 2019: Sitravatinib plus Tislelizumab show promise in platinum-resistant advanced ovarian cancer
Nov 09, 2019: Mirati Therapeutics Presents Data From Ongoing Clinical Trials Of Sitravatinib In Combination With Nivolumab At The SITC 34th Annual Meeting
Oct 23, 2019: Mirati Therapeutics announces presentation of interim phase 2 Sitravatinib data In Urothelial Carcinoma and Oral Cavity Squamous Cell Carcinoma At The SITC 34th Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Antengene Corp Ltd, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by Celldex Therapeutics Inc, 2022
Pipeline by Celon Pharma SA, 2022
Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Exelixis Inc, 2022
Pipeline by F. Hoffmann-La Roche Ltd, 2022
Pipeline by Halia Therapeutics Inc, 2022
Pipeline by HEC Pharma Co Ltd, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Inspirna Inc, 2022
Pipeline by Mediolanum farmaceutici SpA, 2022
Pipeline by Meryx Inc, 2022
Pipeline by Mirati Therapeutics Inc, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Qurient Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Companies, 2022 (Contd..5)
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Antengene Corp Ltd, 2022
Pipeline by Aucentra Therapeutics Pty Ltd, 2022
Pipeline by Celldex Therapeutics Inc, 2022
Pipeline by Celon Pharma SA, 2022
Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Pipeline by Eli Lilly and Co, 2022
Pipeline by Exelixis Inc, 2022
Pipeline by F. Hoffmann-La Roche Ltd, 2022
Pipeline by Halia Therapeutics Inc, 2022
Pipeline by HEC Pharma Co Ltd, 2022
Pipeline by Incyte Corp, 2022
Pipeline by Inspirna Inc, 2022
Pipeline by Mediolanum farmaceutici SpA, 2022
Pipeline by Meryx Inc, 2022
Pipeline by Mirati Therapeutics Inc, 2022
Pipeline by Ono Pharmaceutical Co Ltd, 2022
Pipeline by Pfizer Inc, 2022
Pipeline by Qurient Co Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022
LIST OF FIGURES
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
